Table 2.
Study quality assessment for eligible randomized controlled trials.
| References | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Score |
|---|---|---|---|---|---|---|---|---|---|---|
| Mitchell et al. (2014) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Jindani et al. (2015) | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Seppälä et al. (2014) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 8 |
| Quiñones et al. (2015) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Reinhardt et al. (2017) | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Huberty et al. (2020) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 6 |
| Goldsteina et al. (2017) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| van der Kolk et al. (2014) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Dick et al. (2014) | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 5 |
| Kim et al. (2013) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 6 |
| Omidi et al. (2013) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Carter et al. (2013) | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Possemato et al. (2016) | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 7 |
| Kearney et al. (2013) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Polusny et al. (2015) | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 7 |
| Kelly and Garland (2016) | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
Item 1 = randomization; Item 2 = concealed allocation; Item 3 = similar baseline; Item 4 = blinding of assessors; Item 5 = ≤ 15% dropouts; Item 6 = intention-to-treat analysis; Item 7 = between-group comparison; Item 8 = point measure and measures of variability; Item 9 = isolate exercise intervention; 1 = explicitly described and present in details; 0 = absent, inadequately described, or unclear.